Tempus AI, Inc. filed an 8-K on November 18, 2026, disclosing that it and AstraZeneca AB entered into a Fifth Amendment to their Master Services Agreement on November 16, 2026, establishing a new five-year financial commitment period worth an aggregate of $200 million through December 31, 2031.

Key Highlights

  • Fifth Amendment signed: Tempus AI and AstraZeneca AB executed the Fifth Amendment to their Master Services Agreement, effective January 1, 2027.
  • $200 million aggregate commitment: AstraZeneca committed to $200 million in fees to Tempus AI over the Renewal Term, representing an annual target spend of $40 million.
  • Annual minimum guaranteed: AstraZeneca agreed to a minimum of $32 million in fees in each calendar year of the Renewal Term.
  • Term extended through December 31, 2031: The MSA's term is extended to December 31, 2031, with a possible one-year extension to December 31, 2032 if the $200 million aggregate commitment is not met.
  • Termination shortfall liability: If AstraZeneca terminates the MSA for convenience before fulfilling its financial commitments, it remains liable to Tempus AI for any shortfall of the $200 million commitment.
  • Original agreement dated November 17, 2021: The underlying Master Services Agreement between the parties was originally dated November 17, 2021.

Tempus AI and AstraZeneca Renew Strategic Collaboration Under Fifth MSA Amendment

According to the filing, Tempus AI, Inc. (NASDAQ:TEM) and AstraZeneca AB signed the Fifth Amendment to their Master Services Agreement on November 16, 2026. The amendment is effective as of January 1, 2027, and extends the MSA through December 31, 2031, a period the filing refers to as the "Renewal Term." The amendment also extends strategic collaborator benefits previously provided to AstraZeneca under the existing MSA.

The filing disclosed that AstraZeneca committed to an aggregate of $200 million in fees payable to Tempus AI during the Renewal Term, covering both the MSA and other agreements between the parties and their affiliates. The company reported that this translates to an annual target spend of $40 million across Tempus AI's existing and future products and services, with a guaranteed minimum of $32 million per calendar year. If the full $200 million aggregate commitment has not been fulfilled by the end of the Renewal Term, the filing states the term will be automatically extended by one year, through December 31, 2032, to address the shortfall.

The filing noted that AstraZeneca retains the right to terminate the MSA for convenience at any time. However, according to the amendment's terms as described in the filing, if AstraZeneca has not fulfilled its financial commitments at the time of such termination, it "will be liable to pay the Company for any shortfall of its $200 million financial commitment." The 8-K was signed by James Rogers, Chief Financial Officer of Tempus AI, and filed on November 18, 2026. The full text of the amendment was filed as Exhibit 10.1, with certain portions omitted as not material and treated as private or confidential by the registrant.

What Was Disclosed

Tempus AI disclosed the execution of a Fifth Amendment to its Master Services Agreement with AstraZeneca AB, establishing a $200 million, five-year financial commitment period effective January 1, 2027, through December 31, 2031, with a $32 million annual minimum and shortfall liability provisions.